Find every active Type II DMF holder for a target molecule. Joined to plant attribution, FDA inspection class, and recent shipment volume.
Semaglutide has 88 active Type II DMFs across 64 distinct holders, and the top of the leaderboard is entirely Chinese peptide manufacturers. Zhejiang Peptites, Shenzhen Jymed, and Fujian Genohope each carry four active filings. The pattern reflects the post-2024 surge in GLP-1 API capacity outside the originator.
| # | Holder | Country | Active DMFs | Most-recent filing | Status |
|---|---|---|---|---|---|
| 1 | Shenzhen Jymed Technology | CN · Shenzhen | 4 active | Feb 2026 | NAI |
| 2 | Zhejiang Peptites Biotech | CN · Zhejiang | 4 active | Dec 2025 | NAI |
| 3 | Fujian Genohope Biotech | CN · Fujian | 4 active | Sep 2025 | NAI |
| 4 | Sinopep-Allsino Biopharmaceutical | CN · Anhui | 3 active | Dec 2025 | VAI |
| 5 | Shenzhen Readline Biotech | CN · Shenzhen | 3 active | May 2025 | NAI |
Type the INN. The AI agent matches against the FDA Type II DMF register and returns the active-only cohort with first-filed dates.
Each holder is joined to its inspection class (NAI / VAI / OAI) and recent compliance events at the matched plant.
Citation-anchored brief with holder, country, DMF count, recent filing date, and inspection chip per row. Hand off to qualification.
Inactive DMFs are excluded by default. The list is the pool that can ship API tomorrow.
Most-recent filing date per holder. Recently active holders matter more than dormant ones.
Country chip per holder, inferred from filer name when address records lag. China-led peptide vs India-led small molecule is visible in one row.
FDA Type II DMF register is pulled monthly. Status changes (active to inactive) propagate to the next refresh.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twenty molecules from the live warehouse · count of active FDA Type II DMFs per molecule, 2026 snapshot.
The Type II DMF register is the first signal of supply intent — who has filed paperwork claiming they can make this molecule for the US market. PharmaDB joins the register to plant attribution and inspection class, so the list isn’t paper alone. The underlying table is api_docs; the join is to legal_entities and inspections. Refresh cadence is monthly.
A Drug Master File of Type II is a confidential dossier filed with the FDA covering an active pharmaceutical ingredient (API). It allows ANDA filers to reference the API manufacturer without re-disclosing manufacturing details. Active status means the FDA has not received a deactivation request and the holder has not lapsed annual fees.
Biologics use a different regulatory pathway (BLA / biosimilar BLA) and do not have Type II DMFs. The PharmaDB warehouse covers DMF Types II, III, IV, and V; biosimilar manufacturers surface in trade and inspection views but show zero DMF count here.
The GLP-1 weight-loss boom drove a wave of synthetic peptide API capacity in China starting in 2023. Chinese contract manufacturers lodged the bulk of the 88 active filings; 47 were first filed during 2025 alone. Indian players are present but in the long tail.
The FDA legal-entities register often lists a US agent address rather than the manufacturer's true HQ. PharmaDB infers country from a combination of legal name patterns (city names, brand prefixes) and the address of the matched plant. Manual override flags are available in the catalog.
No — this view is the FDA Type II DMF register only. The companion analysis covers EDQM Certificates of Suitability and is reachable as the Active CEP Holders page.
Monthly. The FDA Type II DMF register publishes monthly with first-filed dates and status. The catalog row carries a last-computed timestamp on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.